Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 5, 2009, Pages 482-491

  Gandhi, Monica ^a   Benet, Leslie Z ^b   Bacchetti, Peter ^a   Kalinowski, Ann ^a   Anastos, Kathryn ^c   Wolfe, Alan R ^b   Young, Mary ^d   Cohen, Mardge ^e,f   Minkoff, Howard ^g   Gange, Stephen J ^h   Greenblatt, Ruth M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e Jr Hospital of Cook County   (United States)

^f RUSH MEDICAL COLLEGE   (United States)

^g MAIMONIDES MEDICAL CENTER   (United States)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiretrovirals; Drug exposure; Efavirenz; HIV; Nevirapine; Pharmacokinetics; Women

Indexed keywords

COCAINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ADULT; ALBUMIN BLOOD LEVEL; AMENORRHEA; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; DIARRHEA; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LABORATORY TEST; LIPID DIET; MAJOR CLINICAL STUDY; ORANGE JUICE; PRIORITY JOURNAL; SIDE EFFECT; CLINICAL TRIAL; DOSE RESPONSE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; STATISTICAL MODEL; TIME;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; BENZOXAZINES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HUMANS; LINEAR MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEVIRAPINE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; YOUNG ADULT;

EID: 65449168796     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31819c3376     Document Type: Article

References (47)

1. Bartlett JA, Buda JJ, von Scheele B, et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr. 2006;41:323-331.
2. Vella S, Palmisano L. The global status of resistance to antiretroviral drugs. Clin Infect Dis. 2005;41:S239-S246.
3. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15:185-194.
4. Britton A, McKee M, Black N, et al. Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy. 1999;4:112-121.
5. Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med. 2002;346:1373-1382.
6. Williams JA, Johnson K, Paulauskis J, et al. So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J Clin Pharmacol. 2006;46:258-264.
7. Huang SM, Lesko LJ, Williams RL. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues. J Clin Pharmacol. 1999;39:1006-1014.
8. U.S. Department of Health and Human Services, Food and Drug Administration (FDA). Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. http://www.fda.gov/Cder/guidance/6359OCC. htm. 2005. Accessed November 21, 2007.
9. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. Epidemiology. 1998;9:117-125.
10. Hooker AC, Foracchia M, Dodds MG, et al. An evaluation of population D-optimal designs via pharmacokinetic simulations. Ann Biomed Eng. 2003;31:98-111.
11. Egge-Jacobsen W, Unger M, Niemann CU, et al. Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. Ther Drug Monit. 2004;26:546-562.
12. Volosov A, Alexander C, Ting L, et al. Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem massspectrometry. Clin Biochem. 2002;35:99-103.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
14. Manjunath G, Sarnak MJ, Levey AS. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens. 2001; 10:785-792.
15. Block G, Hartman AM, Naughton D. A reduced dietary questionnaire: development and validation. Epidemiology. 1990;1:58-64.
16. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet. 1994;26:292-307.
17. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58: 119-133.
18. Brocklehurst P, Volmink J. Antiretrovirals for reducing the risk of motherto-child transmission of HIV infection. Cochrane Database Syst Rev. 2002;(2):CD003510.
19. Gonzalez de Requena D, Bonora S, Garazzino S, et al. Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother. 2005;49:3966-3969.
20. Barrett JS, Labbe L, Pfister M. Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy. Clin Pharmacokinet. 2005;44:591-625.
21. Autar RS, Boffito M, Hassink E, et al. Interindividual variability of oncedaily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother. 2005;56:908-913.
22. Pellegrin I, Breilh D, Birac V, et al. Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens. Ther Drug Monit. 2001;23:332-340.
23. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother. 2003;47: 130-137.
24. Brundage RC, Yong FH, Fenton T, et al. Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother. 2004;48:979-984.
25. Vanhove GF, Kastrissios H, Gries JM, et al. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997;41:2428-2432.
26. Fletcher CV, Acosta EP, Cheng H, et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIVinfected subjects: ACTG 884. AIDS. 2000;14:2495-2501.
27. Floren LC, Wiznia A, Hayashi S, et al. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics. 2003;112(3 pt 1): e220-e227.
28. van Heeswijk RP, Veldkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000;14:F77-F82.
29. Veldkamp AI, Harris M, Montaner JS, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis. 2001;184:37-42.
30. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006;109:1-11.
31. Nevirapine [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc; Ridgefield, CT: 2005.
32. Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet. 2003;42:1071-1088.
33. Almond LM, Edirisinghe D, Dalton M, et al. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virusinfected individuals. Clin Pharmacol Ther. 2005;78:132-142.
34. Erickson DA, Mather G, Trager WF, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999;27: 1488-1495.
35. Lechevrel M, Casson AG, Wolf CR, et al. Characterization of cytochrome P450 expression in human oesophageal mucosa. Carcinogenesis. 1999; 20:243-248.
36. Pellinen P, Stenback F, Kojo A, et al. Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology. 1996;23:515-523.
37. Compton WM, Thomas YF, Conway KP, et al. Developments in the epidemiology of drug use and drug use disorders. Am J Psychiatry. 2005; 162:1494-1502.
38. Hinkin CH, Barclay TR, Castellon SA, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11:185-194.
39. Regazzi M, Villani P, Seminari E, et al. Sex differences in nevirapine disposition in HIV-infected patients. AIDS. 2003;17:2399-2400.
40. Burger D, van der Heiden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006;61:148-154.
41. Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses. 2003;19:825-835.
42. Saito M, Hirata-Koizumi M, Matsumoto M, et al. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf. 2005;28:677-694.
43. Droste JA, Kearney BP, Hekster YA, et al. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41:37-43.
44. Haas DW. Human genetic variability and HIV treatment response. Curr HIV/AIDS Rep. 2006;3:53-58.
45. Ette EI, Williams PJ, Lane JR. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Ann Pharmacother. 2004;38:2136-2144.
46. Ette EI, Williams PJ. Population pharmacokinetics II: estimation methods. Ann Pharmacother. 2004;38:1907-1915.
47. Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother. 2004;38:1702-1706.